Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18
- Monday, October 26, 2020, 7:00
- Finance
- Add a comment
EMERYVILLE, Calif., Oct. 26, 2020 /PRNewswire/ — Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on ophthalmology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug…
About the Author
adminasapcorp has written 39737 stories on this site.